Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22990214 | 1.00 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL23509299 | 0.82 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL22990193 | 0.81 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL22990415 | 0.81 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL22962266 | 0.77 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL22962292 | 0.77 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL22962311 | 0.77 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL22996646 | 0.77 | DRD4 (0.32) | — | |
| SCHEMBL24425054 | 0.75 | OPRM1 (0.32) | — | |
| SCHEMBL22990191 | 0.74 | SLC6A2 (0.40) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
| US-20160340445-A1 | ORALLY AVAILABLE COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS ANTI-ADHESIVE DRUGS FOR TREATING E. COLI INDUCED INFLAMMATORY BOWEL DISEASES SUCH AS CROHN'S DISEASE | NANTES UNIVERSITE (FR) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | CYP2D6 4307/4885 |
| US-20160340445-A1 | ORALLY AVAILABLE COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS ANTI-ADHESIVE DRUGS FOR TREATING E. COLI INDUCED INFLAMMATORY BOWEL DISEASES SUCH AS CROHN'S DISEASE | ICAM1, VCAM1, EPCAM | CYP2D6 1207/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | CYP2D6 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.